Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer

B Jasani, H Navabi, M Adams - Vaccine, 2009 - Elsevier
… monocyte-derived DC treated with Ampligen in vitro, express a … assays to demonstrate that
Ampligen matured DC, have an … to develop a rationale for the use of Ampligen as a non-toxic, …

… cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly [C12U](Ampligen®)

M Adams, H Navabi, B Jasani, S Man, A Fiander… - Vaccine, 2003 - Elsevier
Ampligen ® , on monocyte derived DC, as described below. … study support the capacity of
Ampligen ® to produce a stable … the novel synthetic dsRNA analogue Ampligen ® , may offer a …

A clinical grade poly I: C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

H Navabi, B Jasani, A Reece, A Clayton, Z Tabi… - Vaccine, 2009 - Elsevier
Maturation of dendritic cells (DC) can be triggered in vitro by inflammatory cytokines or Toll-like
receptor (TLR) ligands such as CpG or polyI:C. Corresponding, well-characterized …

Clinical studies with ampligen (mismatched double-stranded RNA).

I Brodsky, DR Strayer, LJ Krueger… - Journal of Biological …, 1985 - europepmc.org
… Additionally, a novel method was developed to monitor Ampligen blood levels. In a survey
of seven patients, Ampligen had a mean plasma half-life of 23 min. Ampligen administration …

Long term improvements in patients with chronic fatigue syndrome treated with Ampligen

DR Strayer, W Carter, KI Strauss, I Brodsky… - Journal of Chronic …, 1995 - Taylor & Francis
… of Ampligen suggested that it might be useful in CFS. This report describes long term
improvements in 15 severely afflicted patients treated with Ampligen. … forms of Ampligen used in …

The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis

E Padalko, D Nuyens, A De Palma… - Antimicrobial agents …, 2004 - Am Soc Microbiol
Ampligen on coxsackie B3 virus-induced myocarditis in C3H/HeNHsd mice. The efficacy of
AmpligenAmpligen at 20 mg/kg of body weight/day was able to reduce the severity of virus-…

Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex

WA Carter, I Brodsky, MG Pellegrino, HF Henriques… - The Lancet, 1987 - Elsevier
… We describe here the effect of ampligen on patients with HIV infection. … increments in
neutralising titre against HIV during ampligen therapy and 2 (nos 6, 10) had no change (data not …

Preclinical studies with Ampligen (mismatched double-stranded RNA).

WA Carter, DR Strayer, HR Hubbell… - Journal of Biological …, 1985 - europepmc.org
… Furthermore, Ampligen demonstrates a much wider … Importantly, Ampligen, the product of a
straight-forward enzymatic … (IFN), is sensitive to Ampligen in a fresh human tumor clonogenic …

Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus

WM Mitchell, DC Montefiori, WE Robinson, DR Strayer… - The Lancet, 1987 - Elsevier
… , mismatched double-stranded RNA polymer ’Ampligen’ inhibits HIV infection of target
lymphoid cells.4 Here we describe our study of the effect ampligen had on the in-vitro virustatic …

Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen

DF Smee, J Gilbert, JA Leonhardt, BB Barnett… - Antiviral research, 1993 - Elsevier
Ampligen required heating at 67C for 16 h then at 37C for 1 h in order to anneal the strands
of the … Ampligen was not lethally toxic nor suppressed weight gain at the two doses tested. …